Perspective on the evolution of cell-based bone tissue engineering strategies

European Surgical Research

Volumn 49, Issue 1, 2012, Pages 1-7

  Jakob, M ^a   Saxer, F ^a   Scotti, C ^a   Schreiner, S ^a   Studer, P ^a   Scherberich, A ^a   Heberer, M ^a   Martin, I ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bioreactor systems; Bone regeneration; Cell based bone graft substitutes; Developmental engineering; Intraoperative graft engineering; Stromal vascular fraction; Tissue engineering

Indexed keywords

ADIPOSE TISSUE; AUTOMATION; BIOREACTOR; BIOTECHNOLOGY; BONE DEFECT; BONE DEVELOPMENT; BONE GRAFT; BONE PROSTHESIS; BONE REGENERATION; BONE TISSUE; CELL DIFFERENTIATION; CELL ISOLATION; CELL THERAPY; CLINICAL ASSESSMENT; EMBRYONIC STEM CELL; ENCHONDRAL OSSIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STROMA CELL; NONHUMAN; OSTEOBLAST; PEROPERATIVE CARE; PRIORITY JOURNAL; REVIEW; STEM CELL; TISSUE ENGINEERING; TISSUE TRANSPLANTATION;

ANIMALS; BIOREACTORS; BONE REGENERATION; BONE TRANSPLANTATION; HUMANS; TISSUE ENGINEERING;

EID: 84863731503     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000338362     Document Type: Review

References (48)

1. Bates P, Ramachandran M: Bone injury, healing and grafting; in Ramachandran M (ed): Basic Orthopaedic Sciences. The Stan-more Guide. London, Hodder Arnold, 2007, pp 123-134.
2. Einhorn TA: The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998; 355(suppl):S7-S21.
3. Zimmermann G, Müller U, Löffler C, Wen-tzensen A, Moghaddam A: Therapieerfolg bei atrophen Tibiaschaftpseudarthrosen Bone Morphogenetic Protein 7 (BMP 7) versus autologe Spongiosaplastik. Unfallchirurg 2007; 110: 931-938.
4. Calori GM, Albisetti W, Agus A, Iori S, Tagliabue L: Risk factors contributing to fracture non-unions. Injury 2007; 38(suppl 2):S11-S18.
5. Ai-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA: Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 2008; 87: 107-118.
6. Schmidmaier G, Capanna R, Wildemann B, Beque T, Lowenberg D: Bone morphogenetic proteins in critical-size bone defects: what are the options? Injury 2009; 40(suppl 3):S39-S43.
7. Boden SD: Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation. Tissue Eng 2000; 6: 383-399.
8. Younger EM, Chapman MW: Morbidity at bone graft donor sites. J Orthop Trauma 1989; 3: 192-195.
9. Ahlmann E, Patzakis M, Roidis N, Shepherd L, Holtom P: Comparison of a nterior and posterior iliac crest bone grafts in terms of harvest-site morbidity and functional outcomes. J Bone Joint Surg Am 2002; 84-A:716-720.
10. Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA: Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996; 329: 300-309.
11. Niedhart C, Pingsmann A, Jürgens C, Marr A, Blatt R, Niethard FU: Complications after harvesting of autologous bone from the ventral and dorsal iliac crest-a prospective, controlled study (in German). Z Orthop Ihre Grenzgeb 2003; 141: 481-486.
12. Sasso RC, LeHuec JC, Shaffrey C, Spine In-terbody Research Group: Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment. J Spinal Disord Tech 2005; 18(suppl):S77-S81.
13. Silber JS, Anderson DG, Daffner SD, Brislin BT, Leland JM, Hilibrand AS, Vaccaro AR, Albert TJ: Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine (Phila Pa 1976) 2003; 28: 134-139.
14. De Long WG Jr, Einhorn TA, Koval K, Mc-Kee M, Smith W, Sanders R, Watson T: Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am 2007; 89: 649-658.
15. Logeart-Avramoglou D, Anagnostou F, Bi-zios R, Petite H: Engineering bone: challenges and obstacles. J Cell Mol Med 2005; 9: 72-84.
16. Deutsch H: High-dose bone morphogenetic protein-induced ectopic abdomen bone growth. Spine J 2010; 10:e1-e4.
17. Smith DM, Cooper GM, Mooney MP, Marra KG, Losee JE: Bone morphogenetic protein 2 therapy for craniofacial surgery. J Craniofac Surg 2008; 19: 1244-1259.
18. Carragee EJ, Hurwitz EL, Weiner BK: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11: 471-491.
19. Fischer J, Kolk A, Wolfart S, Pautke C, Warnke PH, Plank C, Smeets R: Future of local bone regeneration-protein versus gene therapy. J Craniomaxillofac Surg 2011; 39: 54-64.
20. Calori GM, Donati D, Di Bella C, Tagliabue L: Bone morphogenetic proteins and tissue engineering: future directions. Injury 2009; 40(suppl 3):S67-S76.
21. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M: Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001; 344: 385-386.
22. Berner A, Pfaller C, Dienstknecht T, Zellner J, Müller M, Prantl L, Kujat R, Englert C, Fuechtmeier B, Nerlich M, Angele P: Arthro-plasty of the lunate using bone marrow mes-enchymal stromal cells. Int Orthop 2011; 35: 379-387.
23. Cuomo AV, Virk M, Petrigliano F, Morgan EF, Lieberman JR: Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am 2009; 91: 1073-1083.
24. Evans CH, Palmer GD, Pascher A, Porter R, Kwong FN, Gouze E, Gouze JN, Liu F, Stein-ert A, Betz O, Betz V, Vrahas M, Ghivizzani SC: Facilitated endogenous repair: making tissue engineering simple, practical, and economical. Tissue Eng 2007; 13: 1987-1993.
25. Meijer GJ, de Bruijn JD, Koole R, van Blitter-swijk CA: Cell-based bone tissue engineering. PLoS Med 2007; 4:e9.
26. Martin I, Baldomero H, Bocelli-Tyndall C, Slaper-Cortenbach I, Passweg J, Tyndall A: The survey on cellular and engineered tissue therapies in Europe in 2009. Tissue Eng Part A 2011; 17: 2221-2230.
27. Martin I, Wendt D, Heberer M: The role of bioreactors in tissue engineering. Trends Biotechnol 2004; 22: 80-86.
28. Martin I, Smith T, Wendt D: Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products. Trends Biotechnol 2009; 27: 495-502.
29. Banfi A, Muraglia A, Dozin B, Mastrogiaco-mo M, Cancedda R, Quarto R: Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp Hematol 2000; 28: 707-715.
30. Braccini A, Wendt D, Jaquiery C, Jakob M, Heberer M, Kenins L, Wodnar-Filipowicz A, Quarto R, Martin I: Three-dimensiona l per-fusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells 2005; 23: 1066-1072.
31. Scherberich A, Galli R, Jaquiery C, Farhadi J, Martin I: Three-dimensional perfusion culture of human adipose tissue-derived endo-thelial and osteoblastic progenitors generates osteogenic constructs with intrinsic vas-cularisation capacity. Stem Cells 2007; 25: 1823-1829.
32. Güven S, Mehrkens A, Saxer F, Schaefer DJ, Martinetti R, Martin I, Scherberich A: Engineering of large osteogenic grafts with rapid engraftment capacity using mesenchymal and endothelial progenitors from human adipose tissue. Biomaterials 2011; 32: 5801-5809.
33. Salter E, Goh B, Hung B, Hutton D, Ghone N, Grayson WL: Bone tissue engineering bioreactors: a role in the clinic? Tissue Eng Part B Rev 2012; 18: 62-75.
34. Cox G, McGonagle D, Boxall SA, Buckley CT, Jones E, Giannoudis PV: The use of the reamer-irrigator-aspirator to harvest mesen-chymal stem cells. J Bone Joint Surg Br 2011; 93: 517-524.
35. Stafford PR, Norris BL: Reamer-irrigator-as-pirator bone graft and bi Masquelet technique for segmental bone defect nonunions: a review of 25 cases. Injury 2010; 41(suppl 2):S72-S77.
36. Aslan H, Zilberman Y, Kandel L, Liebergall M, Oskouian RJ, Gazit D, Gazit Z: Osteogen-ic differentiation of noncultured immuno-isolated bone marrow-derived CD105+ cells. Stem Cells 2006; 24: 1728-1737.
37. Braccini A, Wendt D, Farhadi J, Schaeren S, Heberer M, Martin I: The osteogenicity of implanted engineered bone constructs is related to the density of clonogenic bone marrow stromal cells. J Tissue Eng Regen Med 2007; 1: 60-65.
38. Fraser JK, Wulur I, Alfonso Z, Hedrick MH: Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotech-nol 2006; 24: 150-154.
39. Housman TS, Lawrence N, Mellen BG, et al: The safety of liposuction: results of a national survey. Dermatol Surg 2002; 28: 971-978.
40. Helder MN, Knippenberg M, Klein-Nulend J, Wuisman PI: Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. Tissue Eng 2007; 13: 1799-1808.
41. Vergroesen PP, Kroeze RJ, Helder MN, Smit TH: The use of poly(L-lactide-co-caprolac-tone) as a scaffold for adipose stem cells in bone tissue engineering: application in a spinal fusion model. Macromol Biosci 2011; 11: 722-730.
42. Müller AM, Mehrkens A, Schäfer DJ, Jaqui-ery C, Güven S, Lehmicke M, Martinetti R, Farhadi I, Jakob M, Scherberich A, Martin I: Towards an intraoperative engineering of osteogenic and vasculogenic grafts from the stromal vascular fraction of human adipose tissue. Eur Cell Mater 2010; 19: 127-135.
43. Miranville A, Heeschen C, Sengenès C, Cu-rat CA, Busse R, Bouloumié A: Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004; 110: 349-355.
44. Scotti C, Tonnarelli B, Papadimitropoulos A, Scherberich A, Schaeren S, Schauerte A, Lopez-Rios J, Zeller R, Barbero A, Martin I: Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proc Natl Acad Sci USA 2010; 107: 7251-7256.
45. Jukes JM, Both SK, Leusink A, Sterk LM, van Blitterswijk CA, de Boer J: Endochondral bone tissue engineering using embryonic stem cells. Proc Natl Acad Sci USA 2008; 105: 6840-6845.
46. Gawlitta D, Farrell E, Malda J, Creemers LB, Alblas J, Dhert WJ: Modulating endochon-dral ossification of multipotent stromal cells for bone regeneration. Tissue Eng Part B Rev 2010; 16: 385-395.
47. Lenas P, Moos M, Luyten FP: Developmental engineering: a new paradigm for the design and manufacturing of cell-based products. Part I: from three-dimensional cell growth to biomimetics of in vivo development. Tissue Eng Part B Rev 2009; 15: 381-394.
48. Lenas P, Moos M, Luyten FP: Developmental engineering: a new paradigm for the design and manufacturing of cell-based products. Part II: from genes to networks: tissue engineering from the viewpoint of systems biology and network science. Tissue Eng Part B Rev 2009; 15: 395-422.